Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1] Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NWXDOlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TWV2lEPTB;MD6wNFY3QSEQvF2= NFPpcXZUSU6JRWK=
MV-4-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T1W2lEPTB;MD6wNVU5PiEQvF2= MWHTRW5ITVJ?
NKM-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDtV|JKSzVyPUCuNFE3QTlizszN MmizV2FPT0WU
ML-2 NHqzS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPydG9yUUN3ME2wMlAyQTh|IN88US=> MlX0V2FPT0WU
BV-173 NUjJbIhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEKzNVQh|ryP MljrV2FPT0WU
RS4-11 NHfqU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDjOo9WUUN3ME2wMlAzPTh5IN88US=> MnyyV2FPT0WU
HL-60 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnLXFdbUUN3ME2wMlAzQTB6IN88US=> NX;MSXRXW0GQR1XS
KY821 M2Xte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmwNItwUUN3ME2wMlAzQTd3IN88US=> MU\TRW5ITVJ?
ECC10 NEnmXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTtTWM2OD1yLkCzO|kzKM7:TR?= MUTTRW5ITVJ?
NCI-H720 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\1OIFKSzVyPUCuNFQxOTFizszN M2fxTnNCVkeHUh?=
QIMR-WIL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMESyPFch|ryP NGK1WZRUSU6JRWK=
KG-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITPc4lKSzVyPUCuNFQ1QDZizszN NHLmUIxUSU6JRWK=
TGW NFvm[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLITWM2OD1yLkC0OlM{KM7:TR?= NITlRZRUSU6JRWK=
ATN-1 NYD5W5RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm5TWM2OD1yLkC0O|M{KM7:TR?= MXvTRW5ITVJ?
RH-18 NWrYUZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITEeVJKSzVyPUCuNFYxPDhizszN NF3NSHpUSU6JRWK=
EW-18 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:2TWM2OD1yLkC2PFQyKM7:TR?= M4raPHNCVkeHUh?=
NB17 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLpTWM2OD1yLkC3NVI1KM7:TR?= NHS4NpFUSU6JRWK=
SK-NEP-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXKTWM2OD1yLkC3NlE{KM7:TR?= NWDje21HW0GQR1XS
P12-ICHIKAWA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm0Z2RKSzVyPUCuNFc4PzhizszN NVrVW|JXW0GQR1XS
KARPAS-45 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DzW2lEPTB;MD6wO|gyPSEQvF2= NXnFOpJ{W0GQR1XS
EW-3 NI\rSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEiwOVMh|ryP Mnr3V2FPT0WU
NB13 NInj[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3exZ2lEPTB;MD6wPFIxOyEQvF2= MkXwV2FPT0WU
NCI-H209 M3[zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjJTWM2OD1yLkC4O|A1KM7:TR?= MmLNV2FPT0WU
NCI-H1092 NIfO[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCSmw4UUN3ME2wMlExOjd3IN88US=> MmXHV2FPT0WU
NH-12 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PPTWlEPTB;MD6xNFc1PCEQvF2= M1TyeHNCVkeHUh?=
697 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUC4N|kh|ryP MXPTRW5ITVJ?
KE-37 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv0bWRKSzVyPUCuNVE{PyEQvF2= NY[0OZpjW0GQR1XS
MOLT-4 NVKxcpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV61d5h7UUN3ME2wMlE2OTZ7IN88US=> MWTTRW5ITVJ?
CHP-134 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W3d2lEPTB;MD6xOlMxPiEQvF2= M4PVXXNCVkeHUh?=
D-283MED M1;IXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\4TWM2OD1yLkG3Olg3KM7:TR?= MVTTRW5ITVJ?
LU-135 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n6NmlEPTB;MD6xPFU2OiEQvF2= MXrTRW5ITVJ?
LU-134-A M3;oO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn6WINKSzVyPUCuNVg3PzFizszN MkW1V2FPT0WU
EM-2 M1v3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHuUm9[UUN3ME2wMlE6QTF6IN88US=> NEXyO2NUSU6JRWK=
LU-139 NHm0VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMkC0PVgh|ryP MVPTRW5ITVJ?
ALL-PO NYn2NY9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMkG5PFgh|ryP NW\XR5hSW0GQR1XS
NB12 NF7FeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHaOJZKSzVyPUCuNlMyOTVizszN NYfQNWIxW0GQR1XS
KP-N-YN NEHhW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HNOGlEPTB;MD6yN|U4OyEQvF2= MoXSV2FPT0WU
BEN MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXrTWM2OD1yLkKzPVY5KM7:TR?= NWXE[Y5mW0GQR1XS
HCC1569 NWHnXJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\Ue2lEPTB;MD6yOVExPiEQvF2= M4jyR3NCVkeHUh?=
HuO9 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[zPWlEPTB;MD6yOlcyPSEQvF2= MV\TRW5ITVJ?
WM-115 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7PTWM2OD1yLkK3O|M5KM7:TR?= NFzsRlNUSU6JRWK=
CCRF-CEM NVrLT|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwM{O1Nlkh|ryP NYDGfWd7W0GQR1XS
IST-SL1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zpVmlEPTB;MD6zOVM1OyEQvF2= NI\NbHRUSU6JRWK=
BE-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX3dVZbUUN3ME2wMlM3PDV7IN88US=> NVXhZ4g1W0GQR1XS
COR-L88 NUO5WG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K2TWlEPTB;MD6zOlU1KM7:TR?= NIfhd5dUSU6JRWK=
DOHH-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNEGwNlMh|ryP MkLaV2FPT0WU
A704 NH[4fFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[0R2lEPTB;MD60NlY4KM7:TR?= NXPk[op1W0GQR1XS
KNS-81-FD NH62[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwNESwNVch|ryP MV\TRW5ITVJ?
RPMI-8226 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULacGs{UUN3ME2wMlQ2PjV{IN88US=> M{LqN3NCVkeHUh?=
TGBC24TKB NUKzZoxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:1Z2lEPTB;MD60OVc4QCEQvF2= NUexR4ZkW0GQR1XS
NCI-H1304 NHjqdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7EWllKSzVyPUCuOFYyPTdizszN NF[4V4hUSU6JRWK=
MOLT-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfrTWM2OD1yLkS2OlE{KM7:TR?= MVfTRW5ITVJ?
EW-22 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXmXY5KSzVyPUCuOFY3PzFizszN MXvTRW5ITVJ?
MS-1 NFjF[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SydWlEPTB;MD60Olk{OyEQvF2= NWDRN2YxW0GQR1XS
RMG-I NHzy[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\kXFFOUUN3ME2wMlQ6PDZ2IN88US=> MWLTRW5ITVJ?
NTERA-S-cl-D1 NUTn[Y5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLnTWM2OD1yLkWwNFE6KM7:TR?= NVrEc2JpW0GQR1XS
NCI-H1048 NHXxRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknjTWM2OD1yLkWwPVU{KM7:TR?= Mn3MV2FPT0WU
SW1417 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXrdlVKSzVyPUCuOVU1OzhizszN Mn3yV2FPT0WU
DB NF;vV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnjOYJKSzVyPUCuOVcxQCEQvF2= MnvoV2FPT0WU
MEG-01 NWG4VmVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXaTWM2OD1yLkW4N|Ih|ryP NHvBSYJUSU6JRWK=
EW-13 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTNTWM2OD1yLkW4N|QyKM7:TR?= NYXJVolEW0GQR1XS
LAMA-84 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;HclBZUUN3ME2wMlU6OjB5IN88US=> M2m2N3NCVkeHUh?=
J-RT3-T3-5 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jz[2lEPTB;MD62NFgxQCEQvF2= NETFOmlUSU6JRWK=
MOLT-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNkWyOlQh|ryP NGnDN3BUSU6JRWK=
DU-4475 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrHUo9KSzVyPUCuOlU1OjdizszN NETSeGlUSU6JRWK=
HAL-01 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nJXWlEPTB;MD63NlU1QSEQvF2= MWPTRW5ITVJ?
RD M3e0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwN{W4PVkh|ryP NHT3S2tUSU6JRWK=
OAW-28 M3;zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXSdYljUUN3ME2wMlc5OzdizszN M3XqfnNCVkeHUh?=
HCC38 NYnYVY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTqTppKSzVyPUCuPFAyQSEQvF2= Ml[4V2FPT0WU
NMC-G1 M3TjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK2TWM2OD1yLkixNVIyKM7:TR?= MWPTRW5ITVJ?
EW-16 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[4XmlEPTB;MD64NVMzQCEQvF2= NH[0cpdUSU6JRWK=
DU-145 NGnBNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fr[2lEPTB;MD64PVkzOyEQvF2= MXPTRW5ITVJ?
HPAF-II NXXTeZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGiy[nhKSzVyPUCuPVI3OjhizszN NILvXWJUSU6JRWK=
A427 M2q1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjGPYFKSzVyPUCuPVMxOjJizszN M1fkWXNCVkeHUh?=
PA-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOUW2OFIh|ryP NFTJe5BUSU6JRWK=
OAW-42 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwOU[xOFYh|ryP NH7yd21USU6JRWK=
L-428 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnTR2hKSzVyPUGuNFEzPSEQvF2= NHG2WlhUSU6JRWK=
COLO-824 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwMEG3NFgh|ryP NFzvelZUSU6JRWK=
P30-OHK M1TvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;LTnpyUUN3ME2xMlA1Pjh6IN88US=> M1HXZXNCVkeHUh?=
NCI-H2170 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[3TWM2OD1zLkC2NlMh|ryP NHfORVJUSU6JRWK=
HCC2998 M{n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j2WGlEPTB;MT6wO|E{PSEQvF2= NYXoUJZUW0GQR1XS
NB14 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjHR4RKSzVyPUGuNVM4PDhizszN M4LOSHNCVkeHUh?=
TGBC1TKB NEjocJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr1bmtKSzVyPUGuNVQyPTJizszN MU\TRW5ITVJ?
KP-N-YS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPLTWM2OD1zLkG2NlM3KM7:TR?= NE\seIZUSU6JRWK=
CAL-120 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X5[WlEPTB;MT6xOlQzQSEQvF2= NXK4Z|RVW0GQR1XS
SBC-1 M2HNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOyTWM2OD1zLkG5NFU{KM7:TR?= MVrTRW5ITVJ?
C32 M2j0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn30TWM2OD1zLkG5NFg5KM7:TR?= NYK3VlB4W0GQR1XS
HCC2157 NHjl[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknmTWM2OD1zLkG5OFk1KM7:TR?= NHm1blhUSU6JRWK=
COLO-792 NGHoO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjTWM2OD1zLkKwNFcyKM7:TR?= MnLiV2FPT0WU
ES7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu1ZVFKSzVyPUGuNlc6PTFizszN MoTrV2FPT0WU
HEL NITjU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jaSmlEPTB;MT6zNVAzQSEQvF2= NWTwZ5dvW0GQR1XS
ES4 NVfxTZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwM{S5PVgh|ryP MYPTRW5ITVJ?
NCI-SNU-1 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\CNmlEPTB;MT6zOlU2PSEQvF2= MoHxV2FPT0WU
MDA-MB-415 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfRZZl1UUN3ME2xMlM5QDVizszN MoXGV2FPT0WU
NCI-H2342 NV33cVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfkWXhOUUN3ME2xMlQxOjZ7IN88US=> MnzwV2FPT0WU
NB69 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXZOZpKUUN3ME2xMlQ3OjdzIN88US=> MnTLV2FPT0WU
D-247MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXnOmxKSzVyPUGuOVEyOjJizszN M3zae3NCVkeHUh?=
SCC-4 M1\Kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvMOnpKSzVyPUGuOVk5QDdizszN MlTZV2FPT0WU
HuH-7 NVLUOXRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwNkeyPVMh|ryP Mn7vV2FPT0WU
A388 NFHUcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPiSmo3UUN3ME2xMlY5PzJ2IN88US=> NVjBTmFxW0GQR1XS
Calu-3 M4X3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnsTWM2OD1zLkewOlk4KM7:TR?= M3fMUHNCVkeHUh?=
NCI-H1648 NIT1OWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfJS2ZKSzVyPUGuO|E1OThizszN MljkV2FPT0WU
NCI-H2052 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD1zLkeyNlAyKM7:TR?= MYTTRW5ITVJ?
Ramos-2G6-4C10 M3Xjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfQWXhTUUN3ME2xMlc{PjV4IN88US=> MnfMV2FPT0WU
DEL NEn1e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPSTWM2OD1zLke0OlkzKM7:TR?= MV3TRW5ITVJ?
SNU-423 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\FdmhKSzVyPUGuO|gyPTdizszN M4DXbXNCVkeHUh?=
COR-L23 NUT3N5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXvWY9WUUN3ME2xMlc6QDd2IN88US=> MnSxV2FPT0WU
OMC-1 NX7sZYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjyeFBKSzVyPUGuPFYxOTZizszN NV72e2RSW0GQR1XS
EW-11 NIn5cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwOUW2OVch|ryP MYLTRW5ITVJ?
HSC-3 NHKwVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHxXldFUUN3ME2xMlk3OzZ3IN88US=> M3\iNXNCVkeHUh?=
MLMA NWXNXYdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTxcodKSzVyPUGuPVY3PzdizszN M1zDVHNCVkeHUh?=
RCM-1 M{DY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzKOndKSzVyPUKuNFA{QTlizszN Ml\zV2FPT0WU
MFE-280 M4\sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJZ4lsUUN3ME2yMlAzQDR6IN88US=> MU\TRW5ITVJ?
ES8 NFjIZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJwMkW0O|Eh|ryP NFfy[3ZUSU6JRWK=
TE-11 NFjJ[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwMkm0O|Mh|ryP NFXP[mNUSU6JRWK=
HuO-3N1 NFjvXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SyTWlEPTB;Mj60PFc5KM7:TR?= M2nLZ3NCVkeHUh?=
MHH-NB-11 NYDnepA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnv[4JKSzVyPUKuOVEyPThizszN M4XzSnNCVkeHUh?=
TGBC11TKB Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwNUe2PFEh|ryP M{m1[HNCVkeHUh?=
HOP-92 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\sPWlEPTB;Mj61PFc1OyEQvF2= Ml7OV2FPT0WU
IGR-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rkWGlEPTB;Mj62NlA{PSEQvF2= NXSzTGZyW0GQR1XS
GOTO M3j6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzpTWM2OD1{Lk[1N|c4KM7:TR?= M1XDWnNCVkeHUh?=
NCI-H1650 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfRTWM2OD1{LkeyNlE2KM7:TR?= M4jSUXNCVkeHUh?=
NCI-H1581 M3e1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELtflRKSzVyPUKuO|k3QDFizszN M170[HNCVkeHUh?=
NCI-H2405 NUXLNGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwOEK3PFIh|ryP NYPHPJNFW0GQR1XS
U-118-MG NVeybJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3VTWM2OD1{Lkm2OFkyKM7:TR?= MVXTRW5ITVJ?
DoTc2-4510 NUDKUlh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\Id2lEPTB;Mz6wNVQyPyEQvF2= MXHTRW5ITVJ?
NCI-H596 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\1eWlEPTB;Mz6wOFk6PyEQvF2= M4nJTnNCVkeHUh?=
MPP-89 M1;oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwMEW2OlYh|ryP MY\TRW5ITVJ?
GCIY M1PPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nreGlEPTB;Mz6yNFQ6OSEQvF2= M4X2TXNCVkeHUh?=
SW626 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fifGlEPTB;Mz6yOFU1OyEQvF2= NFvYblVUSU6JRWK=
OCI-AML2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLR[m5RUUN3ME2zMlMyOjd{IN88US=> NXiwbGE4W0GQR1XS
NBsusSR NU\CN4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPhZ4dtUUN3ME2zMlM1QTN6IN88US=> MY\TRW5ITVJ?
AN3-CA NF7yOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwNESyN|gh|ryP MV3TRW5ITVJ?
EFM-19 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vCRWlEPTB;Mz60PFM{QSEQvF2= M4PYUXNCVkeHUh?=
RVH-421 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176fWlEPTB;Mz61Olg4PyEQvF2= M1;XVHNCVkeHUh?=
5637 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HvVWlEPTB;Mz62NVExOyEQvF2= M37TWHNCVkeHUh?=
PANC-08-13 NUD2SI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjPSnBKSzVyPUOuOlM1PzJizszN MoLxV2FPT0WU
H9 M1jQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNwNkexOFQh|ryP NHnzepJUSU6JRWK=
KARPAS-299 NXn3cJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorvTWM2OD1|Lk[3N|YyKM7:TR?= MYHTRW5ITVJ?
TE-5 NVOwcJRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPTWM2OD1|LkewO|A6KM7:TR?= MWDTRW5ITVJ?
NOS-1 NI\0OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwN{m4N|Qh|ryP MXHTRW5ITVJ?
HH NXvDfIlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPMTWM2OD1|LkizPFY5KM7:TR?= MU\TRW5ITVJ?
769-P NHy4VnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH0XIxLUUN3ME2zMlg6PTFizszN Mm\5V2FPT0WU
CHP-212 M1TlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTNwOUK1OFkh|ryP MoC5V2FPT0WU
NCI-H82 NUW4N3NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fCWGlEPTB;Mz65OVk{PiEQvF2= NUj2SJdVW0GQR1XS
Mo-T NGrFSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLoTWM2OD12LkC0N|EzKM7:TR?= NXHOe21GW0GQR1XS
BB65-RCC Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRwMESzPVkh|ryP NWHZTnVJW0GQR1XS
SW1990 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;lTWM2OD12LkC1PVA5KM7:TR?= NEL2[21USU6JRWK=
LK-2 M3S3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTiTWM2OD12LkGxNlk{KM7:TR?= M1z5b3NCVkeHUh?=
ES5 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj0TWM2OD12LkGzPVg2KM7:TR?= MkPpV2FPT0WU
JVM-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HxWmlEPTB;ND6xPFIzOiEQvF2= M2nyZXNCVkeHUh?=
RPMI-7951 NXPE[ZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwMkK0NVMh|ryP M{\F[HNCVkeHUh?=
Calu-6 NIK3V2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwMke4PFEh|ryP MmL5V2FPT0WU
LC-2-ad MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TMWmlEPTB;ND6yPVU3QCEQvF2= NEWwUZRUSU6JRWK=
SW954 NXvNW2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnjOGdKSzVyPUSuNlk3PiEQvF2= NYiwfWp2W0GQR1XS
H-EMC-SS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LWV2lEPTB;ND6zNVg{OSEQvF2= NHy0VXVUSU6JRWK=
ES3 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXLTWM2OD12LkO1OFQyKM7:TR?= MoPTV2FPT0WU
no-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PDOWlEPTB;ND6zOVU2PCEQvF2= NX3qcIZVW0GQR1XS
LAN-6 M4nTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iyXmlEPTB;ND60OVE5QSEQvF2= NUGzdmJTW0GQR1XS
FTC-133 Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:zS2xVUUN3ME20MlU{QTVizszN MV\TRW5ITVJ?
8505C M2X5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PjTmlEPTB;ND61OFI{KM7:TR?= NFXJXHlUSU6JRWK=
SW620 NYTJWJBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L5bmlEPTB;ND61O|A2PyEQvF2= NELZcFRUSU6JRWK=
BCPAP Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1TWM2OD12Lk[zOFgyKM7:TR?= M1ixWnNCVkeHUh?=
SK-LU-1 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRwNk[wPFkh|ryP MnTYV2FPT0WU
NCI-H1623 NVW0ZWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnuTo9kUUN3ME20MlcxOjJ6IN88US=> NHnJOIdUSU6JRWK=
C2BBe1 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwN{SwNFgh|ryP M4rjcXNCVkeHUh?=
GP5d M{[zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWxTWM2OD12Lke4N|g5KM7:TR?= MmrFV2FPT0WU
NB6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwOE[yNFQh|ryP MkSxV2FPT0WU
MDA-MB-157 M3zCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HLWGlEPTB;ND64PFc3KM7:TR?= NG\wOFhUSU6JRWK=
UMC-11 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHKTWM2OD12Lki4PVY1KM7:TR?= MWTTRW5ITVJ?
HCC1419 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LvN2lEPTB;ND65NFA3OyEQvF2= NHPVUVRUSU6JRWK=
NCI-H2029 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTRwOUSxPFUh|ryP M2PjRnNCVkeHUh?=
LXF-289 M1;TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm1TWM2OD13LkCzO|E6KM7:TR?= NWTFZWltW0GQR1XS
KINGS-1 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSzTWM2OD13LkC3O|Q1KM7:TR?= MnT6V2FPT0WU
HD-MY-Z NIizXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7oTWM2OD13LkKzPVY6KM7:TR?= NYjZOlhiW0GQR1XS
ESS-1 NUm3bVY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvhZW1KSzVyPUWuNlU2QTdizszN NV[zUHV2W0GQR1XS
GI-1 NUm2fndST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmzTWM2OD13LkK3PVI3KM7:TR?= NWSxflV6W0GQR1XS
RPMI-2650 M{jWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLrTWM2OD13LkO2NVYh|ryP NWqxXFg4W0GQR1XS
IA-LM MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1raTWlEPTB;NT6zPVg4OSEQvF2= MkTNV2FPT0WU
KP-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4mzS2lEPTB;NT60OlM{PCEQvF2= NGfZWXVUSU6JRWK=
G-402 NIn4OG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrmNmZKSzVyPUWuOVE5PjVizszN NIrxXVFUSU6JRWK=
OS-RC-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG2TWM2OD13LkWyOlA1KM7:TR?= M2Ptb3NCVkeHUh?=
NCI-H1155 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3L[mZMUUN3ME21MlU1QTV3IN88US=> NXv1bow3W0GQR1XS
OE19 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nlb2lEPTB;NT62PFYzPCEQvF2= NHLxO2lUSU6JRWK=
U-2-OS NHLYVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7lTWM2OD13Lki5NFE{KM7:TR?= NG\rNo9USU6JRWK=
SCC-15 NV7TT21iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzkTWM2OD13LkmzOlYzKM7:TR?= MVzTRW5ITVJ?
NCI-H630 NVi2XoVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rHRWlEPTB;NT65PVQxPCEQvF2= NHSyNZpUSU6JRWK=
PFSK-1 NWq5T|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T2NWlEPTB;Nj6wOVI2QSEQvF2= MX;TRW5ITVJ?
NCI-H1770 NVnqWmVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrLcGJEUUN3ME22MlIxQDd2IN88US=> NFjYTFBUSU6JRWK=
SK-MEL-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fmVmlEPTB;Nj60NlkyPSEQvF2= M3zFdXNCVkeHUh?=
LB1047-RCC MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG2OnVKUUN3ME22MlQ4PjJ3IN88US=> MnuyV2FPT0WU
NCI-H446 NYey[lFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PhNGlEPTB;Nj62NlkzPSEQvF2= NX;I[ol4W0GQR1XS
SW780 NVfoVZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL4VIQxUUN3ME22MlcxOTh3IN88US=> NVTRUIFMW0GQR1XS
NEC8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITDOItKSzVyPU[uO|Y3OyEQvF2= M4\KNnNCVkeHUh?=
NOMO-1 NI\3Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfmUVdKSzVyPU[uO|gyOTFizszN NIrtWIdUSU6JRWK=
COLO-668 NWfMe2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG0OllsUUN3ME22Mlg1Ozh5IN88US=> M4m2UnNCVkeHUh?=
MC116 M4rub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTmTWM2OD14LkmzPFk4KM7:TR?= M1nRbXNCVkeHUh?=
HCC1937 NFTXOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZ[o97UUN3ME22Mlk6OjVzIN88US=> NXnRb5dxW0GQR1XS
NCI-N87 NGjCd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LCeWlEPTB;Nz6xPVI6OyEQvF2= MWXTRW5ITVJ?
COLO-320-HSR NHfHUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLTGlEPTB;Nz6yNlc{QCEQvF2= NGjS[WZUSU6JRWK=
HCC1806 M17RNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTWdGNKSzVyPUeuNlYxPDRizszN MoHiV2FPT0WU
OVCAR-3 NYH6TGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLCOVFKSzVyPUeuN|MxOzhizszN M1\Ve3NCVkeHUh?=
NUGC-3 M{DFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTdwM{m2PVQh|ryP M1\ocnNCVkeHUh?=
SW1783 NWS2bWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHxdJJ{UUN3ME23MlQ{OTd3IN88US=> NXnxUVYxW0GQR1XS
GCT MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvoTWM2OD15LkW2PVA3KM7:TR?= Mme0V2FPT0WU
NCI-H2126 NIjPcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXyTWM2OD15LkezOlI2KM7:TR?= MXrTRW5ITVJ?
MEL-HO NInlOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkixTWM2OD15Lke3NFU1KM7:TR?= MXnTRW5ITVJ?
CAPAN-1 NH;LVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3tTWM2OD15Lke3N|U4KM7:TR?= NWnaXHFyW0GQR1XS
SW756 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTdwN{izN|Mh|ryP MYrTRW5ITVJ?
SKG-IIIa MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnh[mNKSzVyPUeuPFE5QTJizszN MoewV2FPT0WU
HCE-T NFzKPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTdwOEe3PFMh|ryP NFO4OHNUSU6JRWK=
Ca-Ski MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfPUJF5UUN3ME23Mlk6Ozh|IN88US=> NYXQXIxwW0GQR1XS
COLO-684 NXzXN4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TaTGlEPTB;OD6wNVgyQCEQvF2= NX\1U4x7W0GQR1XS
KYSE-70 NHm5dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfFbY5QUUN3ME24MlA4PzJ7IN88US=> M3rC[XNCVkeHUh?=
TI-73 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnub2VKSzVyPUiuNlU5PTFizszN M1rvU3NCVkeHUh?=
BT-20 NGrwUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRThwMk[wOVIh|ryP MlHIV2FPT0WU
MHH-ES-1 NEfkWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThwNUG4N|Qh|ryP MYDTRW5ITVJ?
TE-12 M3PP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\xUI1KSzVyPUiuOVk6OzFizszN NYfNdFU{W0GQR1XS
YH-13 M3HucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELVPFZKSzVyPUiuOlExODhizszN NX;mWWViW0GQR1XS
SF126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\VU2lEPTB;OD64N|g3PSEQvF2= NYTmV|RCW0GQR1XS
J82 M{fwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[yTWM2OD16LkmwNFM5KM7:TR?= MljlV2FPT0WU
RCC10RGB NIDo[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zzOGlEPTB;OD65PVU3OSEQvF2= M3XxUHNCVkeHUh?=
SK-UT-1 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jkUWlEPTB;OT6wOFk1PSEQvF2= MYLTRW5ITVJ?
LB2241-RCC NUHCZWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfGc4FKSzVyPUmuNVkyOzdizszN NUTXR|FSW0GQR1XS
LB996-RCC MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HLb2lEPTB;OT6xPVg6KM7:TR?= MlnYV2FPT0WU
EPLC-272H M4rMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hzd2lEPTB;OT6zO|Y2PyEQvF2= NWjpSFVXW0GQR1XS
CTV-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\MOGlEPTB;OT61OlU{OiEQvF2= MYTTRW5ITVJ?
HSC-2 MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPnTWM2OD17LkW3OVUh|ryP NULVUmdUW0GQR1XS
SK-MEL-28 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHRTWM2OD17Lk[xPFk{KM7:TR?= M{Xx[HNCVkeHUh?=
MMAC-SF MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TEdGlEPTB;OT62PFc2KM7:TR?= M2nvSHNCVkeHUh?=
CP50-MEL-B NVjKUIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2XHF2UUN3ME25Mlc2Pzh{IN88US=> NXfjXYFZW0GQR1XS
HT-1080 M3S2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H5TGlEPTB;OT63O|c{QSEQvF2= M4rmbnNCVkeHUh?=
HEC-1 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHXcYRKSzVyPUGwMlM{PTJizszN MoDlV2FPT0WU
AGS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTTTWM2OD1zMD6zO|Qh|ryP MYPTRW5ITVJ?
GAMG NEf1ZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXZUGtnUUN3ME2xNE42OTZ{IN88US=> M{DnVHNCVkeHUh?=
SW48 M1zX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPhcXJKSzVyPUGwMlUyQDlizszN MlnaV2FPT0WU
U031 NHrud2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDnTWM2OD1zMD61PVA5KM7:TR?= M2HPZnNCVkeHUh?=
OVCAR-5 NXvnVXJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknSTWM2OD1zMD62OFI6KM7:TR?= MUDTRW5ITVJ?
SF295 M33XOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFyLk[3NFQh|ryP MoPlV2FPT0WU
BHT-101 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrONIZSUUN3ME2xNE44OTd5IN88US=> NUewUJh2W0GQR1XS
VMRC-RCZ M4\3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHTTWY6UUN3ME2xNU4{OjBzIN88US=> NHnEb2tUSU6JRWK=
ACHN NF64[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPRbWdKSzVyPUGxMlQzOTFizszN NUDSVVRNW0GQR1XS
NCI-H526 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP2T5VRUUN3ME2xNU42ODR|IN88US=> M4P2dXNCVkeHUh?=
MN-60 M3;qZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnSOWpwUUN3ME2xNU42OzlizszN M2L0S3NCVkeHUh?=
NCI-H2291 NFTZUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3UTWM2OD1zMT61OFY3KM7:TR?= NE\XOHlUSU6JRWK=
SCC-25 M3LKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL4b5JZUUN3ME2xNU44PTV4IN88US=> MVLTRW5ITVJ?
SK-MEL-2 M3PGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPjbJJKSzVyPUGxMlc3OzdizszN M{CwUXNCVkeHUh?=
SN12C M3fnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[0N5RKSzVyPUGxMlk{PTVizszN NUTWOmJnW0GQR1XS
NCI-H69 M1yyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXEdHdKSzVyPUGyMlQzOzRizszN Mn3EV2FPT0WU
ME-180 NYnteIJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNb5B1UUN3ME2xNk44ODV2IN88US=> M3\n[HNCVkeHUh?=
MC-IXC NXL0cJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;mb3JKSzVyPUGyMlc2OThizszN NH3YbWdUSU6JRWK=
NCI-H2347 NVq1bIpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPoTWM2OD1zMj63OlE1KM7:TR?= MUTTRW5ITVJ?
M059J NFrU[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHF[HRKSzVyPUGyMlc4OjdizszN M3Hm[XNCVkeHUh?=
A2058 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnjTWM2OD1zMj64OlgyKM7:TR?= M2PPVXNCVkeHUh?=
VA-ES-BJ MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G3cWlEPTB;MUKuPFc5PSEQvF2= M1nBZXNCVkeHUh?=
Ca9-22 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFftNWRKSzVyPUGyMlk1PTFizszN MljtV2FPT0WU
KNS-42 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF{Lkm5PFQh|ryP NEL6Z29USU6JRWK=
LoVo MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjSVoZKSzVyPUGzMlI{OTNizszN NWrBfpZ1W0GQR1XS
AM-38 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXQNXJKSzVyPUGzMlI2PjZizszN M3PLZXNCVkeHUh?=
NB5 NHG4PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF|LkO3OVIh|ryP NHjUO4ZUSU6JRWK=
L-363 NV24cJN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[1RWlEPTB;MUOuOFA{OyEQvF2= NVzhN4Z6W0GQR1XS
SK-MEL-30 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[wWWlEPTB;MUSuNFY1PSEQvF2= M3\xZnNCVkeHUh?=
NCI-H1563 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7JfZdZUUN3ME2xOE43ODN7IN88US=> MUTTRW5ITVJ?
NCI-H2228 NXmzZlBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF2Lk[wO|ch|ryP NULKd4F5W0GQR1XS
MFM-223 M4\rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDzc25KSzVyPUG1MlE5OTNizszN Mn\3V2FPT0WU
LB831-BLC NX\lNmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C4eGlEPTB;MUWuNlc3PyEQvF2= NF\0SplUSU6JRWK=
SW872 M1nk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\US2lEPTB;MUWuN|A5PiEQvF2= NGDobpJUSU6JRWK=
NCI-H522 M1ry[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:xRlNYUUN3ME2xOU4{OzB4IN88US=> NEKzdlFUSU6JRWK=
EW-1 NYnFOJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljkTWM2OD1zNT61OFYzKM7:TR?= NEXZWY1USU6JRWK=
HN NEe1RWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TCPWlEPTB;MUWuOVk1OiEQvF2= NGDBNZlUSU6JRWK=
SW837 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHUdFRKSzVyPUG1Mlc5PDdizszN NVrS[VRsW0GQR1XS
SCC-9 NUX2NIxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF3LkixNVQh|ryP MkPNV2FPT0WU
MKN7 NV7oe|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\rb5BCUUN3ME2xOU46PzN{IN88US=> MYnTRW5ITVJ?
KYSE-410 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\oTWM2OD1zNj61PVEh|ryP NG\U[4NUSU6JRWK=
SK-N-DZ NInvT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnNPXFKSzVyPUG2MlYyOTZizszN NHTMU2FUSU6JRWK=
COR-L105 NXXsbYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL0SFBZUUN3ME2xOk43PTJ6IN88US=> NIHxcYhUSU6JRWK=
LB2518-MEL NUjZPXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\K[VRsUUN3ME2xOk45Ozh7IN88US=> MnjCV2FPT0WU
OVCAR-4 M1nJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PrV2lEPTB;MU[uPFg3OiEQvF2= M1zFS3NCVkeHUh?=
TK10 MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33NcmlEPTB;MU[uPVQ4OyEQvF2= MkXzV2FPT0WU
KNS-62 NHLRXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjubVVKSzVyPUG2Mlk4PzdizszN M4LhRXNCVkeHUh?=
RPMI-8866 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWz[YhKSzVyPUG3MlE4OzJizszN MWTTRW5ITVJ?
HuP-T4 NETiPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF5LkK0PVUh|ryP Mn6xV2FPT0WU
CGTH-W-1 NFTIcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y0W2lEPTB;MUeuOVIyQSEQvF2= MUnTRW5ITVJ?
T-24 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7pVHhGUUN3ME2xO{42OzR5IN88US=> NE[0bIVUSU6JRWK=
HT-3 NHLPSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljmTWM2OD1zNz61PVE1KM7:TR?= M3ThNnNCVkeHUh?=
KS-1 M4r4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LNb2lEPTB;MUeuOlc{KM7:TR?= NHK4doZUSU6JRWK=
NCI-H1792 NFflZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjJTWM2OD1zNz63PVgh|ryP M2\aOHNCVkeHUh?=
ABC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrITWM2OD1zNz64NVQyKM7:TR?= Mn7KV2FPT0WU
BPH-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37xUGlEPTB;MUiuNVY5PSEQvF2= MVzTRW5ITVJ?
A431 NYjtTXNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:3TWM2OD1zOD60NVI4KM7:TR?= MmHmV2FPT0WU
T98G MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnKO413UUN3ME2xPE42OTV5IN88US=> M1;UTHNCVkeHUh?=
BHY M1j3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF6Lki2PUDPxE1? NHHKOIpUSU6JRWK=
Capan-2 NHzn[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD1zOD65NFc5KM7:TR?= NVrBbIdvW0GQR1XS
MDA-MB-175-VII MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojlTWM2OD1zOD65NlA6KM7:TR?= NYrWbHRzW0GQR1XS
CAL-27 NWTNSFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rqVWlEPTB;MUmuNFQ5PyEQvF2= NVK3OJROW0GQR1XS
AsPC-1 M{\XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ufodKUUN3ME2xPU45PjV5IN88US=> NFXDTIhUSU6JRWK=
KU812 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF7Lkm1O|Mh|ryP NELNOJdUSU6JRWK=
NCI-H441 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\CWJZKSzVyPUKwMlAxOSEQvF2= MoD6V2FPT0WU
Mewo NXfT[5BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH0OVRKSzVyPUKwMlEzQDhizszN Ml7GV2FPT0WU
SK-MEL-24 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJyLkG0O|ch|ryP NXj4ZVl[W0GQR1XS
NCI-H727 MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjQUGVKSzVyPUKwMlI4ODRizszN MWjTRW5ITVJ?
EKVX NID5WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPUWlFKSzVyPUKwMlYxPiEQvF2= NIrWT3hUSU6JRWK=
RT-112 NUjob4VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3frSGlEPTB;MkCuOlEzOiEQvF2= MkTVV2FPT0WU
CAMA-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD1{MD65PFA{KM7:TR?= NXv0XIVxW0GQR1XS
SW900 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj6TWM2OD1{MT6wNVQ6KM7:TR?= MW\TRW5ITVJ?
NCI-H23 NGSydpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jhcmlEPTB;MkGuNVI4PyEQvF2= NGXqZo1USU6JRWK=
SK-PN-DW Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf2PYFDUUN3ME2yNU4yPjR7IN88US=> NIHZWoVUSU6JRWK=
BB30-HNC M{H3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHaTWM2OD1{MT6yO|Q2KM7:TR?= MkThV2FPT0WU
VM-CUB-1 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rQ[WlEPTB;MkGuN|U{PiEQvF2= NULiSlB1W0GQR1XS
IST-MEL1 NUfz[29TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjsTWM2OD1{MT6zOlkzKM7:TR?= MXvTRW5ITVJ?
CTB-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjFXGtKSzVyPUKxMlQ4PTVizszN M33FN3NCVkeHUh?=
LCLC-103H NGLj[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7UPGJKSzVyPUKyMlE2QDJizszN MVjTRW5ITVJ?
PANC-03-27 NVPVTIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qzdWlEPTB;MkKuOVE3QSEQvF2= MWnTRW5ITVJ?
HTC-C3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xsc2lEPTB;MkKuOVU2PSEQvF2= NXPO[FNnW0GQR1XS
TE-8 M3Li[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETGUnZKSzVyPUKzMlI2PjVizszN NVrve3B1W0GQR1XS
NCI-H292 M{jEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ThUmlEPTB;MkWuN|U{PiEQvF2= M1\DXnNCVkeHUh?=
COLO-680N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XTeWlEPTB;MkWuOlMzQSEQvF2= MUHTRW5ITVJ?
KYSE-520 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ3Lk[0OEDPxE1? M3;KNHNCVkeHUh?=
NB10 NWHoPYhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXwTWM2OD1{Nj6zNVE4KM7:TR?= MWrTRW5ITVJ?
NCI-H661 NWTJbY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPhSFhKSzVyPUK2MlQ4OTNizszN M1W1NXNCVkeHUh?=
GMS-10 NVLEU4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDmToZKSzVyPUK2Mlg3OzhizszN MUjTRW5ITVJ?
NCI-H2122 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfJTWM2OD1{Nj65PVk5KM7:TR?= MUDTRW5ITVJ?
OVCAR-8 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:zSWJtUUN3ME2yO{4xPjN6IN88US=> NF3vRpBUSU6JRWK=
DJM-1 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HkPGlEPTB;MkeuNVQ2PCEQvF2= NXT2NnNWW0GQR1XS
UACC-893 NFvpeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3tUlBbUUN3ME2yO{46QDd6IN88US=> MWjTRW5ITVJ?
C8166 NXnJboJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ6Lk[5N|gh|ryP NEKyXGhUSU6JRWK=
NCI-H1693 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ6Lk[5O|Uh|ryP MYTTRW5ITVJ?
TYK-nu MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNyLkCzOFUh|ryP M{PzZXNCVkeHUh?=
SW1710 NEXVTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfKTWM2OD1|MD6xNlYh|ryP M1nNcHNCVkeHUh?=
A375 NVnRPYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PyVWlEPTB;M{CuN|I1OyEQvF2= M4XEcnNCVkeHUh?=
HMV-II MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfLZm5pUUN3ME2zNU4{PTl{IN88US=> MmH3V2FPT0WU
NCI-H2087 NUnnU3ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPDcWg1UUN3ME2zNU43OzV{IN88US=> M4jEUnNCVkeHUh?=
CAL-54 NGHrNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHmTWM2OD1|MT63NlQyKM7:TR?= NWrLWYxoW0GQR1XS
HCC70 NHLMW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN{LkGzPFch|ryP MWDTRW5ITVJ?
ES1 NHv6fpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli0TWM2OD1|Mj6zNFYzKM7:TR?= Ml;vV2FPT0WU
NCI-H1355 M3j0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofzTWM2OD1|Mz6yNFQh|ryP MXzTRW5ITVJ?
CFPAC-1 NXXqcVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN|LkKzN|Ih|ryP NFjRS25USU6JRWK=
MKN28 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTN|LkO4NFkh|ryP M2jMNXNCVkeHUh?=
HDLM-2 NF7BbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C4eWlEPTB;M{OuOlk{OSEQvF2= MoX6V2FPT0WU
PANC-10-05 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\RTGlEPTB;M{SuNVAyPCEQvF2= M3;6V3NCVkeHUh?=
SAS NXTmXXI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2yTWM2OD1|ND60OVY2KM7:TR?= NXfBN3oyW0GQR1XS
HCC1395 NGTTZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN2LkexPFYh|ryP NVvpNJhDW0GQR1XS
8305C NX;BdoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWzUoJKSzVyPUO1Mlg1OTVizszN NXrWW3E4W0GQR1XS
KM12 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGyTWM2OD1|Nj63OVQ4KM7:TR?= MULTRW5ITVJ?
SW1116 M4rJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DyUWlEPTB;M{euOVk6OiEQvF2= Mn;0V2FPT0WU
SK-MEL-1 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuyUIVKSzVyPUO4MlM{QDlizszN NXPJSlFmW0GQR1XS
HCC2218 M3rSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP3enBHUUN3ME2zPE43PTF7IN88US=> NEexZlhUSU6JRWK=
T84 NH\0O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLMSI5KSzVyPUO4Mlc1ODlizszN NUG3PXd3W0GQR1XS
ETK-1 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHBU40{UUN3ME2zPU4xOjJizszN M4XtUnNCVkeHUh?=
COLO-800 NFKwfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnwdGIzUUN3ME2zPU4{QDZ6IN88US=> NUPweo16W0GQR1XS
CAL-12T M2S3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW5TWM2OD1|OT61NlgyKM7:TR?= MXLTRW5ITVJ?
ACN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTRyLkS5NVEh|ryP M2fUXnNCVkeHUh?=
SJSA-1 M4iybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRzLkG1PVYh|ryP MUDTRW5ITVJ?
PSN1 NWnFcVJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGb4lKSzVyPUSxMlE4PDlizszN MkPoV2FPT0WU
D-566MG MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7vTWM2OD12MT6yNFg3KM7:TR?= M1m2O3NCVkeHUh?=
EGI-1 M2T6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR{LkSyPEDPxE1? NWH1SnFKW0GQR1XS
A204 M2HJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR{Lk[zPFgh|ryP NEjwSnpUSU6JRWK=
Saos-2 NXzmXZJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLSTWM2OD12Mj64N|Y6KM7:TR?= NWDNSYNzW0GQR1XS
SNU-C2B MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\JcZRqUUN3ME20N{43QDd6IN88US=> M{\0VHNCVkeHUh?=
HLE M1\m[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n4S2lEPTB;NESuNFg2PiEQvF2= MnrwV2FPT0WU
SW1463 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDscoJJUUN3ME20OE46QTdzIN88US=> MUjTRW5ITVJ?
DSH1 NXLBbWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG4TWM2OD12NT6wNFM{KM7:TR?= M1W2V3NCVkeHUh?=
MCF7 M1n5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPpTWM2OD12NT61NFUyKM7:TR?= MmHBV2FPT0WU
K5 NHTBWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDDcYkxUUN3ME20OU46PDB3IN88US=> NVvsNnRSW0GQR1XS
NCI-H358 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPDb5FKSzVyPUS3MlIyPSEQvF2= MmnpV2FPT0WU
NCI-H2030 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjyeXNtUUN3ME20O{4zOzd2IN88US=> MoHOV2FPT0WU
SW948 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR5LkS2OEDPxE1? NHHVVI9USU6JRWK=
BALL-1 NF\xU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjuSlF7UUN3ME20O{43OTZ6IN88US=> MYnTRW5ITVJ?
TE-9 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXKemRKSzVyPUS3Mlk2QDFizszN M3TRNHNCVkeHUh?=
SK-N-FI Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR6LkCzOVgh|ryP M1i4VHNCVkeHUh?=
KALS-1 NHLMR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR6LkGyPFkh|ryP NWXRbGd[W0GQR1XS
HO-1-N-1 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG2TWM2OD12OD63OFQ2KM7:TR?= NHX0bZJUSU6JRWK=
NCI-H2452 M3HEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTNSIlCUUN3ME20PU4yOTV{IN88US=> NEDCbVBUSU6JRWK=
OC-314 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jMZmlEPTB;NEmuOlg{PCEQvF2= NFfldXBUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID